Beijing Konruns Pharmaceutical Co Ltd - Asset Resilience Ratio

Latest as of March 2026: 10.55%

Beijing Konruns Pharmaceutical Co Ltd (603590) has an Asset Resilience Ratio of 10.55% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 603590 net working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

CN¥430.11 Million
≈ $62.94 Million USD Cash + Short-term Investments

Total Assets

CN¥4.08 Billion
≈ $596.62 Million USD All company assets

Resilience Assessment

Moderate
Financial Resilience Level

Asset Resilience Ratio Trend (2019–2025)

This chart shows how Beijing Konruns Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 603590 current and non-current assets.

Liquid Assets Composition Over Time

This chart breaks down Beijing Konruns Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read 603590 total debt and obligations for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥430.11 Million 10.55%
Total Liquid Assets CN¥430.11 Million 10.55%

Asset Resilience Insights

  • Moderate Liquidity: Beijing Konruns Pharmaceutical Co Ltd has 10.55% of assets in liquid form.
  • While adequate for normal operations, this level may limit flexibility during economic stress.
  • The company has significant short-term investments, indicating active treasury management.

Beijing Konruns Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio

Compare Beijing Konruns Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
CSL Ltd
AU:CSL
Biotechnology 0.41%
Vaxcyte Inc
NASDAQ:PCVX
Biotechnology 41.54%
Bachem Holding AG
SW:BANB
Biotechnology 0.00%
Definium Therapeutics, Inc.
NASDAQ:DFTX
Biotechnology 38.51%
Chongqing Zhifei Bio Products
SHE:300122
Biotechnology -0.08%
HLB Co. Ltd
KQ:028300
Biotechnology 3.29%
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
Biotechnology 2.30%
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
Biotechnology 0.12%

Annual Asset Resilience Ratio for Beijing Konruns Pharmaceutical Co Ltd (2019–2025)

The table below shows the annual Asset Resilience Ratio data for Beijing Konruns Pharmaceutical Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 12.22% CN¥500.43 Million
≈ $73.23 Million
CN¥4.09 Billion
≈ $599.23 Million
+0.72pp
2024-12-31 11.50% CN¥450.66 Million
≈ $65.95 Million
CN¥3.92 Billion
≈ $573.57 Million
+1.01pp
2023-12-31 10.48% CN¥396.41 Million
≈ $58.01 Million
CN¥3.78 Billion
≈ $553.25 Million
+2.30pp
2022-12-31 8.19% CN¥280.37 Million
≈ $41.03 Million
CN¥3.42 Billion
≈ $501.16 Million
+7.92pp
2021-12-31 0.27% CN¥9.04 Million
≈ $1.32 Million
CN¥3.37 Billion
≈ $493.33 Million
-4.52pp
2020-12-31 4.79% CN¥181.36 Million
≈ $26.54 Million
CN¥3.79 Billion
≈ $553.96 Million
+4.73pp
2019-12-31 0.06% CN¥2.00 Million
≈ $293.16K
CN¥3.17 Billion
≈ $464.43 Million
--
pp = percentage points

About Beijing Konruns Pharmaceutical Co Ltd

SHG:603590 China Biotechnology
Market Cap
$661.05 Million
CN¥4.52 Billion CNY
Market Cap Rank
#10884 Global
#2997 in China
Share Price
CN¥28.41
Change (1 day)
+0.18%
52-Week Range
CN¥28.13 - CN¥57.36
All Time High
CN¥65.00
About

Beijing Konruns Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of pharmaceuticals in China and internationally. The company offers agkistrodon acutus hemocoagulase under Suling trade name, a single-component hemocoagulase clinical hemostatic drug for surgical operations. It is also involved in the development of drug candidates, including ZY5301 that is in p… Read more